• 4 notifications referring to situation on 1, 2, 3 and 6 August 2018
  • Threshold crossed: 5%
  • Latest holding: 5.04%

Brussels (Belgium), 8 August 2018 - 20:00 (CEST) - regulated information

1.

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 4 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 2, 3, 6 and 7 August 2018 respectively.

In the first and in the third notification, BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights and equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 1 August and on 3 August 2018 respectively.

In the second and in the fourth notification, BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has increased and has crossed the 5% threshold on 2 and again on 6 August 2018.

On 1 August 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 075 218 UCB shares with voting rights (versus 9 138 257 shares in its previous notification also dated 2 August 2018 but referring to its shareholding on 31 July 2018), representing 4.67% of the total number of shares issued by the company (194 505 658) (versus 4.70% in the previous notification) as well as 622 197 equivalent financial instruments (versus 625 727 in its previous notification) representing 0.32% of the total number of shares issued by the company (same percentage as in the previous notification).

On 6 August 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 182 900 UCB shares with voting rights, representing 4.72% of the total number of shares issued by the company, as well as 623 970 equivalent financial instruments, representing 0.32% of the total number of shares issued by the company.

2. Content of the notifications

2.1 The information mentioned hereafter was identical in all notifications:

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:
  • Threshold crossed (in %): 5%
  • Denominator: 194 505 658.
  • Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the 'Chain of Control' tab.

2.2 The first transparency notification dated 2 August 2018 included the following specific information:

  • Date on which the threshold is crossed: 1 August 2018.
  • Notified details:

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going below 5%.

2.3. The second transparency notification dated 3 August 2018 included the following specific information:

  • Date on which the threshold is crossed: 2 August 2018.
  • Notified details:

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going above 5%.

2.4. The third transparency notification dated 6 August 2018 included the following specific information:

  • Date on which the threshold is crossed: 3 August 2018.
  • Notified details:

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going below 5%.

2.5. The fourth transparency notification dated 7 August 2018 included the following specific information:

  • Date on which the threshold is crossed: 6 August 2018.
  • Notified details:

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going above 5%.

3. Further information

This press release and the detailed transparency notifications are available on UCB SA/NV's website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

Investor Relations

Antje Witte

Investor Relations, UCB

T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,

Investor Relations, UCB

T+32.2.559.9588, isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Attachments

  • Original document
  • Permalink

Disclaimer

UCB SA published this content on 08 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 08 August 2018 18:13:05 UTC